TAFALGIE
Financiado
The first in-class non-opioid drug for treating moderate, severe, and persistent...
The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance
Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous prote...
Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal. Our ambition: to become the reference player in the field of pain medication by designing and proposing new active pharmaceutical ingredients for non-opioid analgesics, in a context marked by the opioid crisis, through the development of first-in-class polypeptides derived from TAFA4 and its peptide derivatives. We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain - mild, moderate, and severe -, as well as for the prevention of chronic pain.
ver más
Duración del proyecto: 33 meses
Fecha Inicio: 2024-02-14
Fecha Fin: 2026-11-30
Fecha Fin: 2026-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-14
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
17M€
Líder del proyecto
TAFALGIE THERAPEUTICS
No se ha especificado una descripción o un objeto social para esta compañía.
